Find NINDS Clinical Trials

Study Title Sort descending Disorders Status Study Location Clinical Trials ID
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients Multiple Sclerosis Completed Maryland NCT00001669
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) Completed Multiple U.S. Locations NCT00451204
A Futility Trial of Sirolimus in Multiple System Atrophy Multiple System Atrophy Terminated New York NCT03589976
A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers Completed Maryland NCT04007263
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis Multiple Sclerosis Recruiting Maryland* NCT04025554
Assessment of Patients With Multiple Sclerosis (MS) Multiple Sclerosis, HTLV-1-Associated Myelopathy (HAM)/Tropical Spastic Paraparesis (TSP) Completed Maryland NCT00001156
Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Recruiting Multiple U.S. Locations NCT02461459
Biomarkers in Multiple Sclerosis Multiple Sclerosis Completed Maryland NCT00325988
Brain Function in Primary Lateral Sclerosis Completed Maryland NCT00071435
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis Completed Maryland NCT00334516
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis Multiple Sclerosis Completed Maryland NCT00432900
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy Not Yet Recruiting Maryland* NCT05849467
Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis Multiple Sclerosis Recruiting Multiple U.S. Locations NCT04495556
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing Recruiting Maryland* NCT04394871
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx Completed Multiple U.S. Locations NCT00211887
Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO) Completed Maryland NCT01805024
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS) Completed Michigan NCT00809224
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis NCT00004457
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study Multiple Sclerosis Recruiting Multiple U.S. Locations NCT04754542
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) Multiple Sclerosis Terminated Maryland NCT01212094